NEW YORK, Nov. 17, 2015 /PRNewswire/ -- Levi & Korsinsky, LLP announces that it has commenced an investigation of Clovis Oncology, Inc. ("Clovis" or the "Company") (NASDAQGS: CLVS) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
On November 16, 2015, Clovis disclosed that potential approval of its lung cancer treatment rociletinib will likely be delayed because the FDA has asked for more data concerning the use of two different dosages and their response rates. Upon this news, shares of Clovis fell more than 70% on intraday trading. To obtain additional information about the investigation, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
SOURCE Levi & Korsinsky, LLP